{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T19:40:39Z","timestamp":1792525239981,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"DOI":"10.1038\/s41391-026-01168-7","type":"journal-article","created":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T07:07:55Z","timestamp":1792480075000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["MRI and PSMA PET\/CT: Foes or friends for the early detection of prostate cancer?"],"prefix":"10.1038","author":[{"given":"Rossano","family":"Girometti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6995-246X","authenticated-orcid":false,"given":"Gianluca","family":"Giannarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Crestani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Urso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,20]]},"reference":[{"key":"1168_CR1","first-page":"02114","volume":"S0302-2838","author":"P Cornford","year":"2026","unstructured":"Cornford P, van den Bergh RCN, Briers E, Chiu P, Eberli D, Epure A, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2026 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2026;S0302-2838:02114\u20137.","journal-title":"Eur Urol"},{"key":"1168_CR2","doi-asserted-by":"publisher","first-page":"469","DOI":"10.6004\/jnccn.2025.0052","volume":"23","author":"DE Spratt","year":"2025","unstructured":"Spratt DE, Srinivas S, Adra N, Ahmed B, An Y, Bitting R, et al. Prostate Cancer, Version 3.2026, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Netw. 2025;23:469\u201393.","journal-title":"J Natl Compr Canc Netw"},{"key":"1168_CR3","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.eururo.2024.08.022","volume":"87","author":"V Kasivisvanathan","year":"2025","unstructured":"Kasivisvanathan V, Wai-Shun Chan V, Clement KD, Levis B, Ng A, Asif A, et al. VISION: An Individual Patient Data Meta-analysis of Randomised Trials Comparing Magnetic Resonance Imaging Targeted Biopsy with Standard Transrectal Ultrasound Guided Biopsy in the Detection of Prostate Cancer. Eur Urol. 2025;87:512\u201323.","journal-title":"Eur Urol"},{"key":"1168_CR4","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.eururo.2020.03.048","volume":"78","author":"NJ Sathianathen","year":"2020","unstructured":"Sathianathen NJ, Omer A, Harriss E, Davies L, Kasivisvanathan V, Punwani S, et al. Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in the Detection of Clinically Significant Prostate Cancer in the Prostate Imaging Reporting and Data System Era: A Systematic Review and Meta-analysis. Eur Urol. 2020;78:402\u201314.","journal-title":"Eur Urol"},{"key":"1168_CR5","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1001\/jamaoncol.2024.5497","volume":"11","author":"CA Hamm","year":"2025","unstructured":"Hamm CA, Asbach P, P\u00f6hlmann A, Schoots IG, Kasivisvanathan V, Henkel TO, et al. Oncological Safety of MRI-Informed Biopsy Decision-Making in Men With Suspected Prostate Cancer. JAMA Oncol. 2025;11:145\u201353.","journal-title":"JAMA Oncol"},{"key":"1168_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35968","volume":"131","author":"RS Grant","year":"2025","unstructured":"Grant RS, Kakani P, Movva P, Daskivich TJ, Raman SS, Sisk AE, et al. Identifying cribriform and intraductal histology on magnetic resonance imaging-assisted biopsy for patients with intermediate-grade prostate cancer: Implications for active surveillance. Cancer. 2025;131:e35968.","journal-title":"Cancer"},{"key":"1168_CR7","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1097\/JU.0000000000004498","volume":"213","author":"S Sandlow","year":"2025","unstructured":"Sandlow S, Carbunaru S, Sun Z, Ofori B, Liu Y, Li E, et al. Negative Predictive Value of a Prostate MRI in Black Men: Implications for Biopsy Decision-Making. J Urol. 2025;213:713\u201321.","journal-title":"J Urol"},{"key":"1168_CR8","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.233337","volume":"312","author":"B Oerther","year":"2024","unstructured":"Oerther B, Nedelcu A, Engel H, Schmucker C, Schwarzer G, Brugger T, et al. Update on PI-RADS Version 2.1 Diagnostic Performance Benchmarks for Prostate MRI: Systematic Review and Meta-Analysis. Radiology. 2024;312:e233337.","journal-title":"Radiology"},{"key":"1168_CR9","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.eururo.2021.08.002","volume":"80","author":"L Emmett","year":"2021","unstructured":"Emmett L, Buteau J, Papa N, Moon D, Thompson J, Roberts MJ, et al. The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study. Eur Urol. 2021;80:682\u20139.","journal-title":"Eur Urol"},{"key":"1168_CR10","unstructured":"Buteau JP, Moon D, Fahey MT, Roberts MJ, Ayati N, Papa N et al. Effect of [68Ga]Ga-PSMA-11 PET-CT in the diagnosis of prostate cancer in men with equivocal or clinically high-risk non-suspicious findings on multiparametric MRI (PRIMARY2): a multicentre, non-inferiority, phase 3, randomised controlled trial. Lancet Oncol. 2026; S1470204526001208."},{"key":"1168_CR11","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1007\/s00259-022-06089-w","volume":"50","author":"WP Fendler","year":"2023","unstructured":"Fendler WP, Eiber M, Beheshti M, Bomanji J, Calais J, Ceci F, et al. PSMA PET\/CT: joint EANM procedure guideline\/SNMMI procedure standard for prostate cancer imaging 2.0. Eur J Nucl Med Mol Imaging. 2023;50:1466\u201386.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1168_CR12","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.231879","volume":"311","author":"BM Priv\u00e9","year":"2024","unstructured":"Priv\u00e9 BM, Isra\u00ebl B, Janssen MJR, Van Der Leest MMG, De Rooij M, Van Ipenburg JA, et al. Multiparametric MRI and18 F-PSMA-1007 PET\/CT for the Detection of Clinically Significant Prostate Cancer. Radiology. 2024;311:e231879.","journal-title":"Radiology"},{"key":"1168_CR13","doi-asserted-by":"publisher","first-page":"5728","DOI":"10.1007\/s00330-026-12395-w","volume":"36","author":"AB Dias","year":"2026","unstructured":"Dias AB, Barentsz J, Allen C, Baroni RH, Fali\u0144ska H, Gaudiano C, et al. Prostate MRI quality improvement: a Roadmap from the ESUR Prostate MRI Working Group. Eur Radiol. 2026;36:5728\u201344.","journal-title":"Eur Radiol"},{"key":"1168_CR14","doi-asserted-by":"crossref","unstructured":"Sonni I, Weiner AB, Doddipalli S, Deol M, Ban D, Kim HO et al. Clinical, Pathologic, and Imaging Variables Associated with Prostate Cancer Detection by PSMA PET\/CT and Multiparametric MRI. J Nucl Med 2024; jnumed.124.268443.","DOI":"10.2967\/jnumed.124.268443"},{"key":"1168_CR15","doi-asserted-by":"publisher","unstructured":"Wagner T, Emberton M, Caglic I, Priftakis D, Giganti F, Kasivisvanathan V et al. PSMA PET: the answer to MRI-occult prostate cancer. or another mirage? Eur Radiol. 2026. https:\/\/doi.org\/10.1007\/s00330-026-12596-3.","DOI":"10.1007\/s00330-026-12596-3"},{"key":"1168_CR16","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/bju.15736","volume":"130","author":"G Ptasznik","year":"2022","unstructured":"Ptasznik G, Papa N, Kelly BD, Thompson J, Stricker P, Roberts MJ, et al. High prostate-specific membrane antigen (PSMA) positron emission tomography (PET) maximum standardized uptake value in men with PI-RADS score 4 or 5 confers a high probability of significant prostate cancer. BJU Int. 2022;130:5\u20137.","journal-title":"BJU Int"},{"key":"1168_CR17","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1111\/bju.15710","volume":"129","author":"YJL Bodar","year":"2022","unstructured":"Bodar YJL, Veerman H, Meijer D, de Bie K, van Leeuwen PJ, Donswijk ML, et al. Standardised uptake values as determined on prostate-specific membrane antigen positron emission tomography\/computed tomography is associated with oncological outcomes in patients with prostate cancer. BJU Int. 2022;129:768\u201376.","journal-title":"BJU Int"},{"key":"1168_CR18","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.eururo.2025.10.013","volume":"89","author":"MJ Karpinski","year":"2026","unstructured":"Karpinski MJ, Hober\u00fcck S, Fendler WP, Civan C, Bundschuh RA, Thomas C, et al. Association Between the PRIMARY Score at Staging Prostate-specific Membrane Antigen Positron Emission Tomography and Overall Survival Among Patients with Newly Diagnosed Prostate Cancer: Findings from the International, Multicenter PROMISE Registry. Eur Urol. 2026;89:123\u20137.","journal-title":"Eur Urol"},{"key":"1168_CR19","doi-asserted-by":"crossref","unstructured":"Farolfi A, Sgro CMP, Brusa I, Dall\u2019Olio D, Romei F, Presutti M et al. PSMA PET\/CT\u2013Targeted Biopsy in Men with Negative or Equivocal Multiparametric MRI and Exploratory Dynamic Total-Body PET: The FUPERMAN Study. J Nucl Med 2026; jnumed.126.272108.","DOI":"10.2967\/jnumed.126.272108"},{"key":"1168_CR20","doi-asserted-by":"publisher","first-page":"4424","DOI":"10.1007\/s00259-026-07829-y","volume":"53","author":"E Lopci","year":"2026","unstructured":"Lopci E, Lazzeri M, Saita A, Saitta C, Disconzi L, Colombo P, et al. 68)Ga]PSMA-11 PET\/CT vs. mpMRI in patients with a high suspicion of prostate cancer and previous negative biopsy: head to head, parallel, prospective trial (PROSPET-BX). Eur J Nucl Med Mol Imaging. 2026;53:4424\u201335. https:\/\/doi.org\/10.1007\/s00259-026-07829-y.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1168_CR21","doi-asserted-by":"crossref","unstructured":"Urso L, Giannarini G, Girometti R, Crestani A, Bauckneht M Re: Effect of [68Ga]Ga-PSMA-11 PET-CT in the Diagnosis of Prostate Cancer in Men with Equivocal or Clinically High-risk Non-suspicious Findings in Multiparametric MRI (PRIMARY2): A Multicentre, Non-inferiority, Phase 3, Randomised Controlled Trial. Eur Urol. 2026; S0302283826022682.","DOI":"10.1016\/j.eururo.2026.07.012"},{"key":"1168_CR22","doi-asserted-by":"crossref","unstructured":"Chernysheva D, Di Bello F, Avesani G, Baboudjian M, Barret E, Breda A et al. ProBIOPSY: A Multidisciplinary International Consensus on Standards for Prostate Biopsy. Eur Urol. 2026; S0302283826022335.","DOI":"10.1016\/j.eururo.2026.08.009"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01168-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01168-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01168-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T19:02:58Z","timestamp":1792522978000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01168-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,20]]},"references-count":22,"alternative-id":["1168"],"URL":"https:\/\/doi.org\/10.1038\/s41391-026-01168-7","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,20]]},"assertion":[{"value":"31 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"GG is or has been an advisory board member for Astellas, AstraZeneca, Curium, Ferring, Hauora Med, Johnson & Johnson, MSD, and Pfizer; has received lecture honoraria from Astellas, Bayer, Johnson & Johnson, Pierre Fabre, and Recordati; and participates or has participated in clinical trials run by Ipsen, Johnson & Johnson, and Pierre Fabre. RG, AC and LU do not have conflicts to disclose.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}